Navigation Links
Co-Opting Technology for the Sake of Weight Loss
Date:12/7/2010

TUESDAY, Dec. 7 (HealthDay News) -- Might technologies and gadgets so popular with today's young adults be corralled to help them lose weight?

Two agencies at the U.S. National Institutes of Health hope to find out.

The agencies are co-funding seven clinical trials that will examine how to use text messaging, online social networking, Bluetooth-enabled scales and other technology to help young people control their weight and, in the process, protect their hearts.

"These studies have the potential to teach us about successfully engaging young adults in achieving a healthy weight at a critical time in their lives," Dr. Susan B. Shurin, acting director of the National Heart, Lung and Blood Institute, one of the sponsoring agencies, said in an institute news release. The other is the National Institute of Child Health and Human Development.

"Learning effective strategies for weight management further empowers young adults to protect their future heart health," she said. "These studies are designed to provide evidence to help us guide young adults toward approaches that work and allow them to choose the options that work best for them."

The approaches being tested in the trials include:

  • The use of iPod Touch, webinars and podcasts to deliver a behavioral weight-loss program to young adults trying to quit smoking.
  • Internet-based programs to promote the health of pregnant women and new mothers.
  • A for-credit course that includes Web-based social networking to prevent weight gain in college students.
  • The use of text message reminders and wearable exercise monitors to improve a weight-loss program.
  • Behavioral intervention using cell phones, Facebook and the Internet.

The studies, called the Early Adult Reduction of Weight Through Lifestyle Intervention trials, will include participants 18 to 35 years old and will focus on promoting weight management throu
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Three NHS Trusts Choose BigHand Voice Technology Under YHCPC Framework Agreement
2. Gold at Forefront of Nanotechnology Revolution
3. Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeants Pet Care Products, Inc.
4. Embark Health Selects the Jellyvision Lab's Interactive Conversation Technology to Educate Website Visitors on Advance Directives
5. First Breakthrough in Water Heating Technology!
6. New Technology Could Widen Reach of Vaccines
7. WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010
8. Nanotechnology could help Arab region
9. Genetic health risks in children of assisted reproductive technology
10. Mennen Medical Launches the VitaLogik 6000, a Pre-Configured Multi-Parameter Patient Monitor with New High Performance Wireless Technology
11. New cardiac CT technology drastically reduces patient radiation exposure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Co-Opting Technology for the Sake of Weight Loss
(Date:7/31/2014)... of invasive lionfish causing fish poisoning may be unfounded. ... derbies and targeted fisheries may remain the best way ... to know for sure whether a lionfish is toxic: ... lionfish were first reported off the coast of Florida ... number ever since. They,re now found in marine habitats ...
(Date:7/31/2014)... Bedford Commons OB-GYN partnered with ... ReEnergizers to do what Christina Haag, the practice ... the community all while still offering the greatest service ... to women’s health needs for every stage of their ... care ( Gynecology ), worked diligently with their marketing ...
(Date:7/31/2014)... 31, 2014 Today, Good Neighbor ... enhance patient care by kicking off another year ... The first of many education sessions and initiatives ... 2014, Good Neighbor Pharmacy and AmerisourceBergen’s annual conference. ... Services (CMS) Star Measures were a highlight and ...
(Date:7/31/2014)... 2014 Ticket Down is a ... Dick’s Sporting Goods Park in suburban Denver on Tuesday, ... soccer team has found a second home competing on American ... time playing international friendly games and will look to have ... Goods Park in Commerce City, Colorado. The match will be ...
(Date:7/31/2014)... HealthDay Reporter , THURSDAY, July 31, ... food, TVs or cigarettes, but people of ancient times commonly ... speculates on some reasons why. Using CT scans of ... the American Southwest, researchers have found evidence of widespread atherosclerosis ... build up, eventually leading to heart attack or stroke. ...
Breaking Medicine News(10 mins):Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 2Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 4Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 3Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 2Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 3
... drug prolonged progression-free survival, study finds , , SATURDAY, ... Avastin to chemotherapy lengthened progression-free survival in women ... Previous studies have found that adding Avastin (bevacizumab) ... with advanced breast cancer actually doubled progression-free survival. ...
... Anti-angiogenesis drug prolonged progression-free survival, study finds , , ... drug Avastin to chemotherapy lengthened progression-free survival in ... , Previous studies have found that adding Avastin ... women with advanced breast cancer actually doubled progression-free ...
... Phase II studies demonstrated potential for pazopanib as a single,agent treatment for ... -- In patients with stage I-III non-small cell lung cancer, 86 ... experienced a reduction in tumor volume ... overall response rate of 35 percent. The ...
... AIDS Walk, Run and Wellness Festival with ... at 9:30 a.m., Walk at 10 a.m., BOSTON, May 31 ... weekend, took a break from her rehearsal,on Friday night to meet ... Walk Boston., (Photo: http://www.newscom.com/cgi-bin/prnh/20080531/CLSA004 ), The 23rd ...
... , A study by Indiana University researchers found ... elderly study participants and their postural stability -- or ... with recent findings by other researchers involving the brain ... probe cognitive function effective at identifying people with poorer ...
... manufacturing, unreliable delivery of the drug , , FRIDAY, May ... drug rotigotine help relieve restless legs syndrome (RLS), according ... -- which stimulate the body,s dopamine system -- are ... rotigotine is already used to treat Parkinson,s disease. This ...
Cached Medicine News:Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:Sunday's AIDS Walk Boston at the Esplanade Gets Tribute from Cyndi Lauper at True Colors Concert Tour Launch Rehearsal 2Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Rotigotine Skin Patch May Ease Restless Legs Symptoms 2
(Date:7/31/2014)... -- Cryoport, Inc. (OTCBB: CYRX) today announced financial results ... Recent Operating Highlights , Achieved ... month period ended June 30, 2014 compared to the ... further expand Cryoport,s global reach using the ,powered by ... Immudex, an immunotherapy and vaccine development services company, to ...
(Date:7/31/2014)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... 2014, on Thursday, August 7, 2014 before markets open. ... and conference call at 8:00 a.m. Eastern time (5:00 ... the call and webcast to discuss financial results and ... by calling (800) 708-4540 (domestic) or (847) 619-6397 (international), ...
(Date:7/31/2014)...  Celsion Corporation (NASDAQ: CLSN ) announced ... to discuss its second quarter 2014 financial results at ... participate in the call, interested parties may dial 1-800-533-7954 ... and ask for the Celsion Corporation Second Quarter 2014 ... before the call is scheduled to begin. The call ...
Breaking Medicine Technology:Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Celsion Corporation to Hold Second Quarter 2014 Financial Results 2
... PARK, N.J., Jan. 25, 2012  Shionogi Inc., the U.S.-based ... results from two studies published online today in the ... first study, a randomized, double-blind, placebo-controlled phase III trial ... with problem drooling due to neurologic conditions demonstrated a ...
...  Amorcyte, LLC, a NeoStem, Inc. company (NYSE Amex: ... of the first patient in the Amorcyte PreSERVE ... study is a multicenter, randomized, double-blind, placebo-controlled clinical ... infarct-related artery infusion of AMR-001, an autologous bone ...
Cached Medicine Technology:Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 3Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 4Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 5Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 6Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 7Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 8Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: